Cell number and chondrogenesis in human mesenchymal stem cell aggregates is affected by the sulfation level of heparin used as a cell coating
Jennifer Lei
George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, 30332 Georgia
Search for more papers by this authorElda Trevino
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, 30332 Georgia
Search for more papers by this authorCorresponding Author
Johnna Temenoff
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, 30332 Georgia
Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, 30332 Georgia
Correspondence to: J. S. Temenoff, e-mail: [email protected]Search for more papers by this authorJennifer Lei
George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, 30332 Georgia
Search for more papers by this authorElda Trevino
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, 30332 Georgia
Search for more papers by this authorCorresponding Author
Johnna Temenoff
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, 30332 Georgia
Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, 30332 Georgia
Correspondence to: J. S. Temenoff, e-mail: [email protected]Search for more papers by this authorAbstract
For particular cell-based therapies, it may be required to culture mesenchymal stem cell (MSC) aggregates with growth factors to promote cell proliferation and/or differentiation. Heparin, a negatively charged glycosaminoglycan (GAG) is known to play an important role in sequestration of positively charged growth factors and, when incorporated within cellular aggregates, could be used to promote local availability of growth factors. We have developed a heparin-based cell coating and we believe that the electrostatic interaction between native heparin and the positively charged growth factors will result in (1) higher cell number in response to fibroblast growth factor-2 (FGF-2) and 2) greater chondrogenic differentiation in response to transforming growth factor-β1 (TGF-β1), compared to a desulfated heparin coating. Results revealed that in the presence of FGF-2, by day 14, heparin-coated MSC aggregates increased in DNA content 8.5 ± 1.6 fold compared to day 1, which was greater than noncoated and desulfated heparin-coated aggregates. In contrast, when cultured in the presence of TGF-β1, by day 21, desulfated heparin-coated aggregates upregulated gene expression of collagen II by 86.5 ± 7.5 fold and collagen X by 37.1 ± 4.7 fold, which was higher than that recorded in the noncoated and heparin-coated aggregates. These observations indicate that this coating technology represents a versatile platform to design MSC culture systems with pairings of GAGs and growth factors that can be tailored to overcome specific challenges in scale-up and culture for MSC-based therapeutics. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 1817–1829, 2016.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
Filename | Description |
---|---|
jbma35713-sup-0001-suppinfo.docx4.9 MB | Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: An FDA perspective. Cell Stem Cell 2014; 14: 141–145.
- 2Trounson A, McDonald C. Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell 2015; 17: 11–22.
- 3Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010; 16: 203–209.
- 4Ayerst Bethanie I, Day Anthony J, Nurcombe V, Cool Simon M, Merry Catherine LR. New strategies for cartilage regeneration exploiting selected glycosaminoglycans to enhance cell fate determination. Biochem Soc Trans 2014; 42: 703–709.
- 5Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076–1084.
- 6Winter A, Breit S, Parsch D, Benz K, Steck E, Hauner H, Weber RM, Ewerbeck V, Richter W. Cartilage-like gene expression in differentiated human stem cell spheroids: A comparison of bone marrow-derived and adipose tissue-derived stromal cells. Arthritis Rheum 2003; 48: 418–429.
- 7Zhang L, Su P, Xu C, Yang J, Yu W, Huang D. Chondrogenic differentiation of human mesenchymal stem cells: A comparison between micromass and pellet culture systems. Biotechnol Lett 2010; 32: 1339–1346.
- 8Solchaga LA, Penick K, Goldberg VM, Caplan AI, Welter JF. Fibroblast growth factor-2 enhances proliferation and delays loss of chondrogenic potential in human adult bone-marrow-derived mesenchymal stem cells. Tissue Eng Part A 2010; 16: 1009–1019.
- 9Zieris A, Prokoph S, Levental KR, Welzel PB, Grimmer M, Freudenberg U, Werner C. FGF-2 and VEGF functionalization of starPEG-heparin hydrogels to modulate biomolecular and physical cues of angiogenesis. Biomaterials 2010; 31: 7985–7994.
- 10Lim JJ, Temenoff JS. The effect of desulfation of chondroitin sulfate on interactions with positively charged growth factors and upregulation of cartilaginous markers in encapsulated MSCs. Biomaterials 2013; 34: 5007–5018.
- 11Markway BD, Tan GK, Brooke G, Hudson JE, Cooper-White JJ, Doran MR. Enhanced chondrogenic differentiation of human bone marrow-derived mesenchymal stem cells in low oxygen environment micropellet cultures. Cell Transplant 2010; 19: 29–42.
- 12Romo P, Madigan MC, Provis JM, Cullen KM. Differential effects of TGF-β and FGF-2 on in vitro proliferation and migration of primate retinal endothelial and Muller cells. Acta Ophthalmol 2011; 89: e263–8.
- 13Carlsberg A, Pucci B, Rallapalli R, Tuan RS, Hall D. Efficient chondrogenic differentiation of mesenchymal cells in micromass culture by retroviral gene transfer of BMP-2. Differentiation 2000; 67: 128–138.
- 14Bartosh TJ, Ylostalo JH, Mohammadipoor A, Bazhanov N, Coble K, Claypool K, Lee RH, Choi H, Prockop DJ. Aggregation of human mesenchymal stromal cells into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci 2010; 107: 13724–12729.
- 15Zimmermann JA, McDevitt TC. Pre-conditioning mesenchymal stromal cell spheroids for immunomodulatory paracrine factor secretion. Cytotherapy 2014; 16: 331–345.
- 16Hayashi K, Tabata Y. Preparation of stem cell aggregates with gelatin microspheres to enhance biological functions. Acta Biomater 2011; 7: 2797–2803.
- 17Hortensius RA, Becraft JR, Pack DW, Harley BA. The effect of glycosaminoglycan content on polyethylenimine-based gene delivery within three-dimensional collagen-GAG scaffolds. Biomater Sci 2015; 3: 645–654.
- 18Liang Y, Kiick KL. Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications. Acta Biomater 2014; 10: 1588–1600.
- 19Nie T, Baldwin A, Yamaguchi N, Kiick KL. Production of heparin-functionalized hydrogels for the development of responsive and controlled growth factor delivery systems. J Control Release 2007; 122: 287–296.
- 20Lundin L, Larsson H, Kreuger J, Kanda S, Lindahl U, Salmivirta M, Claesson-Welsh L. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J Biol Chem 2000; 275: 24653–24660.
- 21Miller T, Goude MC, McDevitt TC, Temenoff JS. Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery. Acta Biomater 2014; 10: 1705–1719.
- 22Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007; 446: 1030–1037.
- 23Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 2011; 3: 1–33.
- 24Nakamura S, Ishihara M, Obara K, Masuoka K, Ishizuka T, Kanatani Y, Takase B, Matsui T, Hattori H, Sato T, Kariya Y, Maehara T. Controlled release of fibroblast growth factor-2 from an injectable 6-O-desulfated heparin hydrogel and subsequent effect on in vivo vascularization. J Biomed Mater Res A 2006; 78: 364–371.
- 25Lee J, Wee S, Gunaratne J, Chua J, Smith R, Ling L, Fernig D, Nurcombe V, Cool SM. Structural determinants of heparin–transforming growth factor-β1 interactions and their effects on signaling. Glycobiology 2015; 25: 1491–1504.
- 26Lei J, McLane LT, Curtis JE, Temenoff JS. Characterization of a multilayer heparin coating for biomolecule presentation to human mesenchymal stem cell spheroids. Biomater Sci 2014; 2: 666–673.
- 27Seto SP, Miller T, Temenoff JS. Effect of selective heparin desulfation on preservation of bone morphogenetic protein-2 bioactivity after thermal stress. Bioconjug Chem 2015; 26: 286–293.
- 28Goude MC, McDevitt TC, Temenoff JS. Chondroitin sulfate microparticles modulate transforming growth factor-β1-induced chondrogenesis of human mesenchymal stem cell spheroids. Cells Tissues Organs 2014; 199: 117–130.
- 29Sart S, Tsai AC, Li Y, Ma T. Three-dimensional aggregates of mesenchymal stem cells: Cellular mechanisms, biological properties, and applications. Tissue Eng Part B Rev 2014; 20: 365–380.
- 30Zomer Volpato F, Almodovar J, Erickson K, Popat KC, Migliaresi C, Kipper MJ. Preservation of FGF-2 bioactivity using heparin-based nanoparticles, and their delivery from electrospun chitosan fibers. Acta Biomater 2012; 8: 1551–1559.
- 31Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986; 128: 475–484.
- 32Esko, JD, Linhardt, RJ. Proteins that bind sulfated glycosaminoglycans. In: A Varki, RD Cummings JD Esko, editors. Essentials of Glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009.
- 33Baird A, Schubert D, Ling N, Guillemin R. Receptor- and heparin-binding domains of basic fibroblast growth factor. Proc Natl Acad Sci 1988; 85: 2324–2328.
- 34Bellosta P, Iwahori A, Plotnikov AN, Eliseenkova AV, Basilico C, Mohammadi M. Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis. Mol Cell Biol 2001; 21: 5946–5957.
- 35Hudalla GA, Koepsel JT, Murphy WL. Surfaces that sequester serum-borne heparin amplify growth factor activity. Adv Mater 2011; 23: 5415–5418.
- 36Orth P, Rey-Rico A, Venkatesan JK, Madry H, Cucchiarini M. Current perspectives in stem cell research for knee cartilage repair. Stem Cells Cloning 2014; 7: 1–17.
- 37Lodish H. Post-translational modification of proteins. Enzyme Microb Technol 1981; 3: 178–188.
- 38Aigner T, Gebhard PM, Schmid E, Bau B, Harley V, Pöschl E. SOX9 expression does not correlate with type II collagen expression in adult articular chondrocytes. Matrix Biol 2003; 22: 363–372.
- 39Akiyama H. Control of chondrogenesis by the transcription factor Sox9. Modern Rheumatol 2008; 18: 213–219.
- 40Marlovits S, Hombauer M, Vescei V, Schlegel W. Changes in the ratio of type-I and type-II collagen expression during monolayer culture of human chondrocytes. J Bone Joint Surg Br 2004; 86: 286–295.
- 41Steinmetz N, Bryant S. Chondroitin sulfate and dynamic loading alter chondrogenesis of human MSCs in PEG hydrogels. Biotechnol Bioeng 2012; 109: 2671–2682.
- 42Chen S, Fu P, Cong R, Wu H, Pei M. Strategies to minimize hypertrophy in cartilage engineering and regeneration. Genes Diseases 2015; 2: 76–95.
- 43Fischer J, Aulmann A, Dexheimer V, Grossner T, Richter W. Intermittent PTHrP(1-34) exposure augments chondrogenesis and reduces hypertrophy of mesenchymal stromal cells. Stem Cells Dev 2014; 23: 2513–2523.
- 44Fischer J, Dickhut A, Rickert M, Richter W. Human articular chondrocytes secrete parathyroid hormone-related protein and inhibit hypertrophy of mesenchymal stem cells in coculture during chondrogenesis. Arthritis Rheum 2010; 62: 2696–2706.
- 45Bourguignon LY, Singleton PA, Zhu H, Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor β receptor I in metastatic breast tumor cells. J Biol Chem 2002; 277: 39703–39712.
- 46Hascall V, Esko JD. Hyaluronan. In: RD Cummings, JD Esko, editors. Essentials of Glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009.
- 47Lo YL, Sung KH, Chiu CC, Wang LF. Chemically conjugating polyethylenimine with chondroitin sulfate to promote CD44-mediated endocytosis for gene delivery. Mol Pharm 2013; 10: 664–676.
- 48Bertram K, Krawetz R. Osmolarity regulates chondrogenic differentiation potential of synovial fluid derived mesenchymal progenitor cells. Biochem Biophys Res Commun 2012; 422: 455–461.
- 49Caron M, van der Windt A, Emans P, van Rhijn L, Jahr H, Welting T. Osmolarity determines the in vitro chondrogenic differentiation capacity of progenitor cells via nuclear factor of activated T-cells 5. Bone 2013; 53: 94–102.